Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
about
Silencing Rab14 represses the proliferation and migration of oral squamous cell carcinoma, and enhances cisplatin sensitivity.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.
P2860
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
@en
type
label
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
@en
prefLabel
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
@en
P2093
P2860
P1476
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC
@en
P2093
Adam D Swick
Amal M Javaid
Deric L Wheeler
Emmanuel Sampene
Irene M Ong
Justine Y Bruce
Kwangok P Nickel
Margot C Miller
Michael M Fisher
P2860
P304
P356
10.1158/1535-7163.MCT-17-0115
P577
2017-04-26T00:00:00Z